| Abstract |
: |
Rivastigmine tartrate is an effective reverse cholinesterase inhibitor which binds to both the esteratic and ionic sites of AchE, preventing the enzyme from metabolizing Ach, resulting in higher levels of Ach in the brain. (In Alzheimer’s disease lower levels of Ach leads to impaired memory (dementia) and learning). Thus Rivastigmine tartrate is used in the treatment of mild to moderate dementia of Alzheimer’s disease. Though the drug is rapidly and completely absorbed following oral administration, it shows significant first-pass effect. Its half life is about 1.5 hrs. Gastro intestinal side effects like vomiting, diarrhea, increased acid secretion in stomach and reduced heart rates are reported. The drug Rivastigmine tartrate posses suitable characteristics such as low daily doses (1.5 to 6 mg twice daily), short half-life (1.5 hrs), low molecular weight (400.43 gms) and low melting point (123ºC - 127ºC) which is suitable for incorporation of drug in transdermal drug delivery system. These properties make Rivastigmine tartrate as a model drug for exploring its application as transdermal drug delivery system. To develope a matrix-type transdermal patch containing Rivastigmine tartrate using blend of polymers PVP and EC in the ratios 1:1, 1:3 and 1:5 with 30% Dibutyl phthalate as a plasticizer. |
Copyright to ENGG Journals Publications
